Archive · 24 Jul 2025
Sun Pharma Subsidiaries Settle US Generic Drug Pricing Case for $200M
Sun Pharma's branches have agreed to pay a large sum of money, $200 million, to end a legal dispute in the U.S. This deal involves two of their companies, Sun Pharmaceutical Industries, Inc.
and Taro.
They are paying this money to resolve claims made against them about how they priced some generic drugs.
In return for the payment, the companies are cleared of all accusations from the people who bought the drugs.
The news also slightly increased the company's stock value.
Sun Pharma subsidiaries will pay $200 million to settle a US generic drug pricing antitrust case.
The agreement involves Sun Pharmaceutical Industries, Inc. and Taro.
The payment is in exchange for a full release of all claims by the End Purchaser Plaintiffs.
Sun Pharmaceutical Industries Ltd's shares increased by 0.56% on the BSE.
The settlement resolves claims related to generic drug pricing.
- Who
- Sun Pharmaceutical Industries, Inc., Taro, and the End Purchaser Plaintiffs.
- What
- Sun Pharma subsidiaries agreed to a $200 million settlement.
- When
- The agreement was reached recently.
- Where
- United States
- Why
- To settle claims related to generic drug pricing antitrust.
Plaintiffs
Sun Pharma
Drug Pricing
Plaintiffs
Argued the drug pricing was anticompetitive and harmful to consumers
Sun Pharma
The companies deny the allegations but have agreed to settle
- Companies Involved
- Sun Pharmaceutical Industries, Inc. and Taro
- Settlement Amount
- $200 million
- Legal Issue
- Generic drug pricing antitrust
- Claimants
- End Purchaser Plaintiffs
- Stock Change
- 0.56% increase